(Received for publication July 15, 1944) Urinary 17-ketosteroids or their precursors are thought to arise from the adrenal cortices and the testes (1) . Testosterone propionate is partially excreted as a 17-ketosteroid (2); on the other hand, 17-methyl testosterone is not excreted as such (3 to. 5). It follows that methyl testosterone in contradistinction to testosterone propionate, may be used to study the effect of a testosterone compound on the endogenous production of urinary 17-ketosteroids. The present paper is primarily concerned with the effect of methyl testosterone on the urinary 17-ketosteroids of adrenal origin.
It is essential that such studies be carried out on individuals without functioning testicular tissue, since it is highly probable from animal experiments that testosterone inhibits its own endogenous production in the testis (6 to 8). It is difficult to obtain direct data in humans on the effect of testosterone on the urinary 17-ketosteroids of testicular origin. Thus, whereas the administration of methyl testosterone to a male without disease of the adrenals and testes induced a lowered 17-ketosteroid excretion (Figure 1 ), the entire effect may have been mediated through 1 The expenses of this investigation were defrayed in part by the Josiah Macy, Jr. Foundation and by a grant from the Committee on Endocrinology of the National Research Council. The work described in this paper was done under a contract, recommended by the Committee on Medical Research, between the Office of Scientific Research and Development and the Massachusetts General Hospital. 2 The authors wish to thank the Schering Corporation, Bloomfield, New Jersey, for the generous supplies of methyl testosterone (Oreton-M) and the Ayerst, McKenna and Harrison Company, New York, for the large amounts of chorionic gonadotropin (A.P.L.) used in these studies. 8 Read by title at the 36th annual meeting of the American Society for Clinical Investigation, May 8, 1944. the adrenal cortex. Actually to establish the point it would be necessary to give methyl testosterone to a male patient with Addison's disease. This was done (Figures 2 and 3) , with suggestive but not conclusive results. Such an experiment runs into difficulties because the low initial level of 17-ketosteroid excretion makes the errors introduced by chromogens and other technical errors relatively more significant.
CLINICAL CASES
The influence of methyl testosterone on 17-ketosteroid excretion by individuals without testicular tissue was studied in 4 females with adrenal hyperplasia, 2 normal females, and 1 male with absence of functioning testicular tissue. Of the 4 patients with hyperplasia, 2 had Cushing's syndrome, and 2, the adrenogenital syndrome. Whereas hyperplasia of the adrenal cortices may occur in both of these conditions, it is the authors' belief that in the first of them there is primarily an over-production of a hormone concerned with carbohydrate metabolism (the so-called "sugar" or "S" hormone), while in the second there is an over-production of a hormone concerned with anabolism of protoplasm, and masculinization (the so-called "nitrogen" or "N" hormone) (9) . In Cushing's syndrome there may be a compensatory over-production of "N" hormone as well (9 (1) .
The collection of urine specimens was rigidly supervised to insure accuracy. Cases 1, 3, and 6 were studied on the research ward, and their collections were handled by specially trained personnel. Most of the determinations in these 3 cases were made on aliquots of 72 to 144-hour pools. The other patients in this investigation collected their specimens at home and brought them personally to the laboratory; these individuals were instructed carefully in the method of collection and were questioned frequently to be certain that they followed the method accurately. Most of the determinations in these patients were on specimens that were obtained by pooling in the laboratory two accurately timed night collections. All of the results are reported in terms of amounts per 24 hours.
Methyl testosterone was administered to the patients by mouth in the form of 10 mgm. tablets.
RESULTS
In Case 1,' I. G., No. 350260, a girl of 11 years with classical Cushing's syndrome, the effect of methyl testosterone was studied twice (Figures 4 and 5). It will be noted that during both control periods, the 17-ketosteroid excretion (circa 15 mgm. per 24 hours) was very high for her age (normal, circa 1 to 3 mgm. per 24 hours (17)) and quite constant; that under methyl testosterone therapy the excretion showed a very orderly fall to 4 Further clinical data are published elsewhere (9 a considerably lower value (circa 4 mgm. per 24 hours); that, when the therapy was omitted, the excretion agaln rose.
In Case 2,5 R. B., No. 3397, a woman of 53 years, also suffering from Cushing's syndrome, it will be observed ( Figure 6 ) that the average pretreatment excretion (circa 18 mgm. per 24 hours) was high for an adult woman (normal circa 9 mgm. per 24 hours (1)) and very constant; that the excretion rose both with testosterone propionate and with dehydroisoandrosterone acetate; that under methyl testosterone therapy the excretion showed a gradual fall to a low value (circa 2 mgm. per 24 hours); and that, after discontinuation of methyl testosterone therapy, the excretion again rose to the pre-treatment level.
In Case 3, R. H., No. 401611, a girl of 6 years with congenital adrenogenital syndrome and pseudohermaphroditism, it will be noted ( Figure  7 ) that during the control period, the 17-ketosteroid excretion (circa 15 mgm. per 24 hours) was very high for her age; that under methyl testosterone therapy the excretion showed a steady fall to a lower value (circa 10 mgm. per 24 hours); and that after the therapy was omitted the excretion definitely increased.
In Case 4,6 E. F., No. 240632, a woman of 24 years with a condition similar to Case 3, the average 17-ketosteroid excretion (Figure 8 ) (circa 45 mgm. per 24 hours) was very high during the control period; with methyl testosterone therapy the average level (circa 35 mgm. per 24 hours) was suggestively lower; and, when the drug was discontinued, the average excretion (circa 40 mgm. per 24 hours) was increased.
Case 5, A. S., a woman of 34 years, had no disease, and normal function of the adrenal cortex. It will be observed ( Figure 9 ) that during the control period the average 17-ketosteroid excretion (circa 11.5 mgm. per 24 hours) was slightly above the average for an adult woman (normal, circa 9 mgm. per 24 hours (1)); that during the administration of 20 mgm. of methyl testosterone daily, the 17-ketosteroid excretion tended to be lower; that during the administration of 40 mgm. of methyl testosterone daily, the excretion showed a gradual fall to definitely low values (circa 6 mgm. per 24 hours); and that after discontinua- (Table I ).
The data from these studies are summarized in tration of methyl testosterone, the values for the first 6 days following a change in therapy were omitted in compiling the mean values. In the 9 experiments, the 7 patients had an average excretion of 18.7 mgm. of steroid per 24 hours before, 11.9 mgm. during, and 18.4 mgm. after methyl testosterone administration.
DISCUSSION
The possibility that the decrease in the urinary 17-ketosteroid level during the administration of methyl testosterone is fortuitous and unrelated to the therapy is almost eliminated by the following points: (a) there is a direct relationship between the fall in level and the administration of the therapy, which is clear-cut in Case 1 (both experiments), Case 2, Case 3, Case 5, and Case 7 (Experiment 2); (b) there is a tendency toward a fall in the excretion in all of the other experiments (including the studies of the two males with Addison's disease, and of the male with normal function of the adrenals and of the testes); (c) the fall in the level is gradual suggesting a physiologic alteration rather than a chance variation; (d) there is a rebound to higher or pre-treatment levels with cessation of therapy in all of the experiments in which these studies were made except Experiment 1, Case 7; and (e) the amount of decrease (circa 40 to 60 per cent) in excretion in Case 1 (both experiments), Case (21) . In view of these considerations, it is concluded that the decrease in the urinary 17-ketosteroid level during the administration of methyl testosterone is due to the action of this compound.
Much of the argument to follow depends on the assumption that the 17-ketosteroid excretion in the urine can be used as an index but not a measure of "N" hormone production. We have elsewhere (9) reviewed the considerable circumstantial evidence that the urinary 17-ketosteroids are: (a) largely derived from "N" hormones, and (b) only slightly, if at all, from "S" hormones. We will cite here only one piece of evidence for each of these suppositions. Thus, on the one hand, testosterone (a strong "N" hormone) is excreted largely as androsterone and etiocholanolone both of which are 17-ketosteroids; on the other hand, pre-pubertal children, who in all probability have a normal "S" hormone production, excrete negligible amounts of 17-ketosteroids in the urine.
The experiments herein reported indicate that methyl testosterone interferes with the adrenal cortical mechanism for producing urinary 17-ketosteroids or their precursors. Such an interference might be produced in at least two ways; (a) a direct inhibition by methyl testosterone of § Values during chorionic gonadotropin therapy included in calculating the average excretion (see Figure 11) . I Experiment 2 immediately followed the after-period of Experiment 1 (see Figure 11) In the case of the male gonad, the tropic hormone in question is the luteinizing hormone, LH. Since it has been here shown that methyl testosterone inhibits the 17-ketosteroid production by the adrenal cortex and since the same is thought to be true for the male gonad, these experiments may add one more piece of evidence to that obtained elsewhere (vide infra) that the production of 17-ketosteroids or their precursors from both these organs is stimulated by the same tropic hormone, namely LH. In Figure 12 , an attempt is made to show these hormonal relationships schematically in a normal individual; in Figure 13 , attempts are made to show these relationships both before and after the administration of methyl testosterone in a normal individual, a female patient with Cushing's syndrome, a female patient with adrenogenital syndrome, and a male patient with Addison's disease. There is evidence, besides that here presented, that one tropic hormone of the pituitary stimulates in the male both the cells of the adrenal cortices concerned with the production of 17-ketosteroids and the cells of Leydig. In a previous paper from this clinic (14) , it was pointed out that those eunuchoid patients (the minority) with high titers of follicle-stimulating-hormone in the urine had 17-ketosteroid excretions of the order of magnitude of those seen in normal females. The inference was that these patients suffered from a primary underfunction of the gonads (i.e., eunuchs from an endocrine point of view) with normal function of the adrenal cortices. It was further shown that those eunuchoid patients (the majority) who did not have a high titer of folliclestimulating-hormone in the urine had 17-ketosteroid excretions considerably lower than those in the normal female; the inference was that such patients were suffering from a defective production of 17-ketosteroids in both the adrenal cortices and the testes. This suggested that one hormone stimulated both organs (see Figure 12) . Furthermore, the failure of bilateral orchidectomy in patients with metastatic cancer of the prostate to lower the 17-ketosteroid excretion (24) is in accord with the suggestion that such a procedure removes an inhibitor to the tropic hormone in question and that the resulting increased production of said tropic hormone stimulates increased production of 17-ketosteroids in the adrenal cortices.
Similarly, the observation that the 17-ketosteroid excretion of young adult females tends to rise for a year or more following termination of ovarian function by castration or x-radiation (25, 26) favors the same interpretation. The demonstration that there is a rise in the urinary excretion of luteinizing hormone in the menopausal state (27) also is in accord with the suggested hypothesis. Other circumstantial evidence that the luteinizing hormone stimulates 17-ketosteroid production by the adrenal cortex is summarized in the following paragraphs. Further discussion of the findings that support these contentions, as well as of a small amount of data that do not, may be found elsewhere (28, 29) .
Atrophy of the adrenal cortex has been produced in animals by the administration of testosterone (22, 30 to 40) and progesterone (22, 38, 41, 42) ; while hypertrophy of the cortex has resulted from treatment with estrogens (43 to 59). These effects cannot be produced in hypophysectomized animals in which the adrenal cortex is maintained in a normal state by the administration of adrenocorticotropic hormone (22, 45, 52, 60) . This is evidence that the effects of testosterone, progesterone, and estrogens on the adrenal cortex are brought about through the pituitary. It has been shown that testosterone (6, 38, 61, 62) and progesterone (63 to (52, 76, 101) ; and (2) hypertrophy of the adrenal cortex has been produced by LH preparations that contain insignificant amounts of ACTH (52, 70, 76) , and vice versa (99 to 105). These facts favor the assump-tion that both LH and ACTH affect the adrenal cortex, but not in the same manner. The strength of the evidence derived from the animal experiments cited above would be increased if it could be shown that alterations in the size of the adrenal cortex were correlated with changes in the excretion of 17-ketosteroid or androgenic substances. In most of these investigations, this evidence has not been sought. Pertinent to this discussion, however, are the observations of certain investigators (117, 118) who were able to produce significant enlargement of the seminal vesicles and prostates of castrated rats by means of pituitary extracts which also caused hypertrophy of the adrenal cortices. Since the effect could not be elicited in the absence of the adrenals, it is clear that this gland had been stimulated to secrete an androgenic principle. Another author (119) obtained similar results in castrated male guinea pigs, and also observed a masculinizing effect (hypertrophy of the clitoris) with pituitary extracts in ovariectomized females. Studies to demonstrate directly in man the effect of chorionic gonadotropin on the production of 17-ketosteroids by the adrenal cortex are being conducted.
Since the luteinizing hormone in the female stimulates the production of progesterone (120) , it might be anticipated that large doses of progesterone (like methyl testosterone) would inhibit 17-ketosteroid production from both the adrenal cortices and the male gonads; studies to answer this question also are being conducted.
The evidence here presented suggests that the high 17-ketosteroid excretion in the adrenogenital syndrome is less easily influenced by methyl testosterone than is that in Cushing's syndrome, even though the pathology in both instances is hyperplasia of the adrenal cortices. This finding is consistent with the thought, already expressed elsewhere (9) , that the increased 17-ketosteroid production in Cushing's syndrome is compensatory to the primary pathology which is an increased production of the "S" hormone; such being the case, one would anticipate that when an exogenous source of "N" hormone was made available in the form of methyl testosterone, the endogenous production would quickly recede. In the adrenogenital syndrome, on the other hand, the primary cause of pathology is thought to be a hyperplasia of those cells which produce "N" hormone, and one would anticipate that it would be harder to modify a process which is primary than one which is secondary.
From the clinical point of view, however, the important point is that the over-production of "N" hormone in the adrenogenital syndrome can be reduced. This may be a clue to therapy. Needless to say it is of little value to such a patient to have her endogenous "N" hormone production decreased by taking an exogenous source of "N" hormone. However, if a steroid could be found which inhibits the endogenous source without itself being an androgen, an important advance in the therapy of these unfortunate patients would probably be at hand. Progesterone has not had a beneficial effect in moderate doses (5, 121); it is to be hoped that it may have in very large doses. In any case, the authors feel very strongly that the approach to the problem is in this direction, as nothing is to be gained by subtotal resection of the adrenal cortices (122, 123) .
SUMMARY AND CONCLUSIONS 1. Since 17-methyl testosterone is not excreted as a 17-ketosteroid, it was employed to study the effect of a testosterone compound on the endogenous production of urinary 17-ketosteroids of adrenal origin.
2. The administration of methyl testosterone decreased the urinary 17-ketosteroids of 7 patients in whom the only source of these substances was the adrenal cortices. The patients included: 2 women with adrenal hyperplasia and Cushing's syndrome, 2 women with adrenal hyperplasia and adrenogenital syndrome, 2 women with normal cortical function, and 1 man with adrenal hyperplasia and congenital absence of functioning testicular tissue.
3. The administration of methyl testosterone caused a suggestive but not conclusive decrease in the urinary 17-ketosteroids of 2 male patients with Addison's disease in whom the only source of these substances was the testes. 4 . Since the production of 17-ketosteroids or their precursors by both the adrenal cortex and the male gonad appears to be inhibited by methyl testosterone, it is suggested that the mechanism of inhibition is the same for both glands. 5. This inhibition is attributed to a decreased production of some pituitary tropic hormone, as suggested by animal experiments in the literature. If one accepts this hypothesis, the findings here reported support the thesis that the same tropic hormone, presumably the luteinizing hormone, stimulates both glands.
6. The 17-ketosteroid excretion by patients with the adrenogenital syndrome was less easily influenced by methyl testosterone than was that of patients with Cushing's syndrome. This is further evidence that the elevated 17-ketosteroid excretion in the former condition is a manifestation of the primary pathology, whereas the increased excretion in the latter condition is an indication of a compensatory process.
7. The fact that the 17-ketosteroid excretion in the adrenogenital syndrome can be reduced with methyl testosterone shows that the condition is potentially reversible and gives hope that a nonandrogenic steroid may be found -which will likewise reduce the 17-ketosteroid excretion in this condition.
